N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
AssigneeAllergan, Inc.
InventorsSANTOSH C. SINHA, LIMING WANG, KEN CHOW, MOHAMMED I. DIBAS, MICHAEL E. GARST
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel N-(imidazolidin-2-ylidene)-heterocyclo penta[b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
Claims9
A method of treating a condition associated with the alpha 2 adrenergic receptors, wherein the condition is a skin condition selected from:
- rosacea, sunburn, psoriasis, acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomyatopic dermatitis, photoaging, seborrheic dermatitis, acne, allergic dermatitis, redness of the skin, telangiectasia of the face, rhinophymia, red bulbous nose, acne-like skin eruptions, burning or stinging sensation of the face, erythema of the skin, cutenous hyperactivity with dilation of blood vessels of the skin, Lyell's syndrome, Stevens-Johnson syndrome, erythema multiforme minor and erythema multiforme major, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I
- wherein:
- R1 is hydrogen, C1-8 alkyl or halogen;
- Y is CH or N;
- X is O, S, NR;
- and
- R is H or C1-3 alkyl.
An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective and wherein the packaging material comprises a label which indicates the pharmaceutical agent can be used for treating a condition associated with the alpha 2 adrenergic receptors, wherein the condition is a skin condition selected from:
- rosacea, sunburn, psoriasis, acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomyatopic dermatitis, photoaging, seborrheic dermatitis, acne, allergic dermatitis, redness of the skin, telangiectasia of the face, rhinophymia, red bulbous nose, acne-like skin eruptions, burning or stinging sensation of the face, erythema of the skin, cutenous hyperactivity with dilation of blood vessels of the skin, Lyell's syndrome, Stevens-Johnson syndrome, erythema multiforme minor and erythema multiforme major and wherein said pharmaceutical agent comprises an effective amount of at least one compound of Formula I:
- wherein:
- R1 is hydrogen, C1-8 alkyl or halogen;
- Y is CH or N;
- X is O, S, NR;
- and
- R is H or C1-3 alkyl.
Dependencies are inferred from the claim text.